Could a common drug stop arthritis after a torn ACL?
NCT ID NCT03552705
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether tranexamic acid (TXA), a drug that reduces bleeding, can lower inflammation and protect joint health after an ACL tear. Fifty people aged 18-30 with a recent ACL injury will receive either TXA or a placebo around the time of surgery. The goal is to see if TXA can prevent or delay post-traumatic osteoarthritis, which often develops years after such injuries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tranexamic acid (TXA)
What this could lead to
If it works, this could point toward a simple way to prevent or delay arthritis after ACL injuries.
What could go wrong
This is a small, early-phase trial (50 people) testing a short-term effect. The drug may not meaningfully reduce arthritis risk, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••